康芝药业股份有限公司（以下简称"公司"）于 2008 年被认定为海南省第一批 高新技术企业，2008 年 12 月获得"高新技术企业证书"，并分别于 2011 年、2014 年、2017 年、2020 年通过了再认定。 公司于近期收到海南省科学技术厅、海南省财政厅、国家税务总局海南省税务 局联合发布的《高新技术企业证书》（证书编号：GR202346000200），公司再次顺利 通过了高新技术企业认定，《高新技术企业证书》有效期为 3 年，即连续三年（2023 年、2024 年、2025 年）公司继续享受高新技术企业所得税按 15%税率征收的优惠 政策。本次被认定为高新技术企业不影响公司此前发布的经营业绩及 2023 年度财 务数据。 本次通过高新技术企业的再次认定，是对公司技术实力及研发水平的充分肯 定，利于公司的长远发展，公司将以此为契机，进一步提升公司综合竞争力。 特此公告。 康芝药业股份有限公司 证券代码：300086 证券简称：康芝药业 公告编号：2024-004 康芝药业股份有限公司 关于公司再次通过高新技术企业认定的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈 ...

证券代码：300086 证券简称：康芝药业 公告编号：2024-003 康芝药业股份有限公司 关于公司控股股东部分股份质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 康芝药业股份有限公司（以下简称"公司"）今日接到公司控股股东海南宏氏 投资有限公司（以下简称"宏氏投资"）有将所持有的公司部分股份质押，具体事 项如下： （一）股东股份质押基本情况 | 股东 | 是否为控 股股东及 | 本次质押数 | 占其所 持股份 | 占公司总 | 是否 为限 | 是否为 补充质 | 质押 起始 | 质押到 | 质权人 | 质押用 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 其一致行 | 量（股） | | 股本比例 | | | | 期日 | | 途 | | | 动人 | | 比例 | | 售股 | 押 | 日 | | | | | | | | | | | | | | 海南省融资 | 补充流动 | | 宏氏 投资 | 控股股东 | 1,000 ...

Group 1: Financial Performance - The company's operating revenue is expected to grow by 30%-45% in 2023 compared to 2022, primarily due to increased sales of "four types of drugs" (antipyretics, cough medicines, antibiotics, and antiviral drugs) [2] - Continuous improvement in cost control and efficiency measures has led to a decrease in expenses, resulting in an anticipated increase in net profit year-on-year [2] Group 2: Product Offerings - The main children's medications currently sold by the company include various formulations such as Levocetirizine granules, Ibuprofen granules, and several others targeting common pediatric conditions [3] - The company is focusing on developing more effective and safe influenza prevention and treatment medications in response to the rising flu outbreak rates [3] Group 3: Research and Development - The company has been increasing its R&D investment, aiming to balance continuous investment with cost control to avoid excessive pressure on operations [3] - The proportion of R&D expenses relative to revenue is being managed to ensure sustainable growth and innovation [3] Group 4: Market Trends and Challenges - The decline in birth rates may lead to a more segmented children's medicine market, increasing consumer demands for product quality and safety [3] - The company acknowledges the need to enhance product quality and safety to build a strong brand image and gain consumer trust [3] Group 5: Employee Incentives - Future employee stock ownership plans will depend on various factors, including the company's financial status and market conditions [4] - The company has disclosed a restricted stock incentive plan in June 2023 to motivate employees and enhance their sense of belonging and loyalty [4]

证券代码：300086 证券简称：康芝药业 公告编号：2024-001 康芝药业股份有限公司 关于公司控股股东部分股份质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 康芝药业股份有限公司（以下简称"公司"）今日接到公司控股股东海南宏氏 投资有限公司（以下简称"宏氏投资"）有将所持有的公司部分股份质押，具体事 项如下： （一）股东股份质押基本情况 | 股东 | 是否为控 股股东及 | 本次质押数 | 占其所 | 占公司总 | 是否 | 是否为 | 质押 | 质押到 | | 质押用 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 其一致行 | 量（股） | 持股份 | 股本比例 | 为限 | 补充质 | 起始 | 期日 | 质权人 | 途 | | | 动人 | | 比例 | | 售股 | 押 | 日 | | | | | 宏氏 | | | | | | | 2024. | 2026.1 | 华夏银行股 | 补充流动 | | | 控股 ...

300086 2023-065 公司董事会对程鹏飞先生在担任公司财务总监期间所做出的贡献表示衷心 的感谢! 特此公告。 康芝药业股份有限公司 董 事 会 2023年12月11日 康芝药业股份有限公司（以下简称"公司"）董事会于2023年12月11日收 到财务总监程鹏飞先生提交的书面辞职报告,程鹏飞先生因个人原因申请辞去公 司财务总监职务(原聘任期至2025年12月14日)，其辞职后不在公司担任其他职 务。 根据《公司法》《公司章程》等相关规定，程鹏飞先生的辞职申请自送达 董事会之日起生效。程鹏飞先生辞去财务总监职务不会对公司日常生产经营和 管理产生不利影响。在公司董事会未正式聘任新的财务总监期间，公司董事长 洪江游先生代行公司财务总监职责。公司将尽快依法依规聘任新的财务总监。 截至本公告披露日，程鹏飞先生除获得公司2023年限制性股票激励计划授 予但尚未归属的第二类限制性股票60,000股（占公司总股本的0.013%）外，未 持有公司股份，辞职后其所获授予尚未归属的股份将按照公司《2023年限制性 股票激励计划》的相关规定进行处理。程鹏飞先生不存在应当履行而未履行的 承诺事项，其离任后将继续遵守《上市公司董事 ...

Sales and Market Performance - The company's sales channels are mainly concentrated in the third terminal and OTC, with normal operations in Q3 [2] - The company's overseas income comes from the maternal and child health sector, leveraging the advantages of the Hainan Free Trade Port policy [4] - In the first half of 2023, the company's pediatric drug revenue was 2.28 billion yuan, with a gross margin of 59.13%, a 75.30% year-on-year increase [4] - Adult drug revenue in the first half of 2023 was 556.864 million yuan, with a gross margin of 49.17%, an 8.76% year-on-year increase [4] - Pediatric drug sales revenue is approximately 4 times that of adult drug sales [4] R&D and Product Development - The company plans to increase R&D efforts to develop new high-quality, safe, and effective drugs [3] - Future development plans include focusing on pediatric drug R&D, particularly in innovative formulations for respiratory, digestive, nervous, and skin systems [3] - The company plans to launch 5 first-tier sales products, 3 second-tier sales products, and 6 third-tier sales products [3] - The company is exploring the development of pediatric traditional Chinese medicine and improving production efficiency through centralized production [3] - There are 6 drug R&D projects in the registration process, with 3 products currently undergoing clinical research [5] Inventory and Supply Chain - The Q3 2023 inventory includes a significant proportion of Chinese herbal medicine raw materials, strategically stocked to counter price increases [3] - The company has increased inventory for seasonal products to meet Q4 sales demand [3] - Terminal channel inventory is normal, with no overstocking or backlog [3] Corporate Strategy and Incentives - The company aims to enhance core competitiveness and employee motivation through a restricted stock incentive plan [5] - The performance target for the incentive plan is a 15% increase in revenue [5] - The company plans to revitalize idle assets to improve profitability [3] Regulatory and Market Environment - The company maintains high compliance standards and continuously strengthens its compliance culture [2] - The company is actively monitoring the adjustment of essential drugs and plans to promote pediatric drug products accordingly [3] - The company has products participating in centralized procurement [5]

Financial Performance - The company's revenue for Q3 2023 was ¥118,694,152.72, a decrease of 1.12% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2023 was -¥36,763,835.68, a decline of 68.34% year-on-year[4] - Year-to-date revenue increased by 29.37% to ¥451,718,553.98 compared to the same period last year[4] - Year-to-date net profit attributable to shareholders increased by 81.34% to -¥20,452,467.40 compared to the same period last year[4] - The basic earnings per share for Q3 2023 was -¥0.0817, a decrease of 68.45% year-on-year[4] - The diluted earnings per share for Q3 2023 was also -¥0.0817, reflecting the same decline of 68.45% year-on-year[4] - Total operating revenue for Q3 2023 reached CNY 451,718,553.98, an increase of 29.5% compared to CNY 349,165,788.89 in the same period last year[16] - Total operating costs amounted to CNY 480,764,567.55, up from CNY 468,685,760.75, reflecting a year-over-year increase of 2.3%[16] - Net loss for the period was CNY 23,132,111.59, compared to a net loss of CNY 112,493,434.00 in the previous year, indicating a significant reduction in losses[18] - Basic and diluted earnings per share were both reported at -0.0454, compared to -0.2436 in the previous year, showing improvement in per-share performance despite ongoing losses[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,087,662,073.63, down 8.77% from the end of the previous year[4] - The total assets decreased from CNY 2,288,471,761.40 to CNY 2,087,662,073.63, a decline of approximately 8.8%[15] - Total liabilities decreased from CNY 932,963,148.62 to CNY 746,339,922.43, a reduction of about 20%[15] - The company's equity attributable to shareholders decreased from CNY 1,316,183,105.82 to CNY 1,304,496,288.43, a slight decline of 0.9%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥17,931,054.11, a significant decrease of 520.72% year-on-year[4] - Operating cash inflow totaled ¥492,490,503.81, a decrease of 6.8% from ¥528,229,417.87 in the previous period[22] - Net cash flow from operating activities was -¥17,931,054.11, compared to -¥2,888,761.92 in the previous period, indicating a worsening cash flow situation[22] - Cash outflow from investing activities was ¥41,887,330.99, up from ¥33,300,742.18 in the previous period, leading to a net cash flow from investing activities of -¥38,308,530.99[22] - Cash inflow from financing activities was ¥62,733,890.33, significantly lower than ¥154,312,620.20 in the previous period, resulting in a net cash flow from financing activities of -¥108,929,819.31[22] - The ending balance of cash and cash equivalents was ¥93,319,047.36, down from ¥178,569,049.04 in the previous period[22] - The company received cash from sales of goods and services amounting to ¥433,597,129.16, a decrease from ¥449,701,155.00 in the previous period[22] - Cash received from tax refunds was ¥28,295,272.75, an increase from ¥24,321,061.01 in the previous period[22] - Cash paid for operating activities totaled ¥510,421,557.92, slightly down from ¥531,118,179.79 in the previous period[22] - Cash paid to employees was ¥78,670,556.71, an increase from ¥74,025,064.45 in the previous period[22] Operational Highlights - The company reported non-operating income of ¥1,103,436.86 for the current period, with government subsidies contributing significantly[5] - The company received the "Hebei Province Worker Pioneer" honor for its subsidiary, Hebei Kangzhi Pharmaceutical Co., Ltd.[11] - The company showcased its star anti-allergy product, Levocetirizine Hydrochloride Granules, at the 11th Jiangsu-Zhejiang-Shanghai-Anhui Pediatric Respiratory Forum[12] - Kangzhi Pharmaceutical provided financial assistance to 100 economically disadvantaged disabled girls in Chaozhou through its charity fund[12] Inventory and Current Assets - As of September 30, 2023, the total current assets of Kangzhi Pharmaceutical amounted to CNY 525,767,629.86, a decrease from CNY 670,460,025.37 at the beginning of the year, representing a decline of approximately 21.6%[13] - The cash and cash equivalents decreased significantly from CNY 269,812,342.27 to CNY 104,642,937.86, indicating a reduction of about 61.2%[13] - Inventory levels increased from CNY 170,403,668.09 to CNY 264,127,007.92, reflecting a growth of approximately 55%[13] - Accounts receivable decreased from CNY 71,130,846.60 to CNY 45,663,739.11, a decline of about 35.8%[13] - The company’s long-term investments remained stable at CNY 5,946,251.81[13] - Fixed assets decreased from CNY 890,943,057.14 to CNY 856,787,759.89, a reduction of approximately 3.8%[13] - The company’s total non-current assets remained unchanged at CNY 237,607,487.29 for investment properties[13] Research and Development - Research and development expenses increased to CNY 14,297,192.84, up from CNY 11,781,021.35, representing a growth of 21.5% year-over-year[16] Financial Reporting - The third quarter report was not audited, indicating potential risks in financial reporting accuracy[24]

第六届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）第六届监事会第八次会议于 2023 年 10 月 25 日在海口国家高新技术产业开发区药谷工业园药谷三路 6 号会议室 以现场方式召开。会议通知于 2023 年 10 月 17 日以邮件、电话等方式发出，应 出席本次会议监事 3 名，实际出席监事 3 名。会议由监事会主席高洪常先生主 持。公司监事及相关高级管理人员列席了本次会议。会议的召开符合《中华人民 共和国公司法》《公司章程》等法律法规的规定。 经与会监事认真审议表决，通过了以下议案： 1.以 3 票赞成、0 票反对、0 票弃权审议通过了《公司 2023 年第三季度报 告》。 经审核，监事会认为：公司董事会根据有关法律法规、规范性文件及《公司 章程》有关规定，认真总结并编制了《公司 2023 年第三季度报告》，其内容真 实、准确、完整地反映了公司 2023 年第三季度的经营管理情况，不存在虚假记 载、误导性陈述或重大遗漏。 证券代码：300086 证券简称：康芝药业 公告编号：2023-064 ...

证券代码：300086 证券简称：康芝药业 公告编号：2023-061 康芝药业股份有限公司 经董事会审议，根据广东元宁制药有限公司（以下简称"元宁制药"）实际 情况、公司生产基地发展规划，以及公司经营发展需要，为了有利于进一步整合 公司资源，优化资源配置，提升盈利能力，同意公司以人民币 1200 万元出售元 宁制药 100%股份。同意公司依照《股权转让协议》约定的条款实施本次交易，并 办理相关的交易手续。本次交易完成后公司将不再持有元宁制药股权，元宁制药 将不再被纳入公司合并报表范围。 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）第六届董事会第九次会议于 2023 年 10 月 25 日在海口国家高新技术产业开发区药谷工业园药谷三路 6 号会议室 以现场及通讯方式召开。会议通知于 2023 年 10 月 17 日以邮件、电话等方式发 出，应出席本次会议董事 7 名，实际出席董事 7 名。会议由董事长洪江游先生主 持。公司监事及相关高级管理人员列席了本次会议。会议的召开符合《中华人民 共和国 ...

康芝药业股份有限公司（以下简称"公司"）2023 年 10 月 25 日召 开了第六届董事会第九次会议和第六届监事会第八次会议，审议通过了 《公司 2023 年第三季度报告》全文的议案。 为使投资者全面了解公司的经营成果、财务状况等相关情况，《公司 2023 年第三季度报告》全文于 2023 年 10 月 27 日在中国证监会指定的创 业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露，敬请投资 者注意查阅！ 特此公告。 证券代码：300086 证券简称：康芝药业 公告编号：2023-063 康芝药业股份有限公司 2023 年第三季度报告提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 康芝药业股份有限公司 董 事 会 2023 年 10 月 27 日 ...